Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.

Garcia-Prats AJ, Schaaf HS, Draper HR, Garcia-Cremades M, Winckler J, Wiesner L, Hesseling AC, Savic RM.

PLoS Med. 2019 Apr 30;16(4):e1002789. doi: 10.1371/journal.pmed.1002789. eCollection 2019 Apr.

2.

Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.

Garcia-Cremades M, Pitou C, Iversen PW, Troconiz IF.

AAPS J. 2019 Jan 31;21(2):23. doi: 10.1208/s12248-018-0291-9.

PMID:
30706160
3.

Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts.

Parra-Guillen ZP, Mangas-Sanjuan V, Garcia-Cremades M, Troconiz IF, Mo G, Pitou C, Iversen PW, Wallin JE.

J Pharmacol Exp Ther. 2018 Jul;366(1):96-104. doi: 10.1124/jpet.118.248286. Epub 2018 Apr 24.

PMID:
29691287
4.

Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.

Garcia-Cremades M, Pitou C, Iversen PW, Troconiz IF.

Eur J Pharm Sci. 2018 Mar 30;115:296-303. doi: 10.1016/j.ejps.2018.01.033. Epub 2018 Jan 31.

PMID:
29366960
5.

Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model.

Garcia-Cremades M, Pitou C, Iversen PW, Troconiz IF.

J Pharmacol Exp Ther. 2017 Mar;360(3):445-456. doi: 10.1124/jpet.116.237610. Epub 2016 Dec 27.

PMID:
28028124

Supplemental Content

Loading ...
Support Center